



Pergamon

Corrigendum

Corrigendum to 'Novel 5-Cyclopropyl-1,4-benzodiazepine-2-ones as Potent and Selective I_{Ks}-Blocking Class III Antiarrhythmic Agents': [Bioorg. Med. Chem. Lett. 13 (2003) 1165][†]


John W. Butcher,^{a,*} Nigel J. Liverton,^a David A. Claremon,^a Roger M. Freidinger,^a
Nancy K. Jurkiewicz,^b Joseph J. Lynch,^b Joseph J. Salata,^b Jixin Wang,^b
Christine M. Dieckhaus,^c Donald E. Slaughter^c and Kamlesh Vyas^c

^aDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA

^bDepartment of Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA

^cDepartment of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA

The authors regret that the structure of compound **2** in the above article was incorrect. The correct structure of compound **2** is shown below:



*Corresponding author. Fax: +1-215-652-3971; e-mail: john_butcher@merck.com

[†]doi of original article: 10.1016/S0960-894X(03)00049-0